Loading...
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.
Strengert, Monika Becker, Matthias Ramos, Gema Morillas Dulovic, Alex Gruber, Jens Juengling, Jennifer Lürken, Karsten Beigel, Andrea Wrenger, Eike Lonnemann, Gerhard
Strengert, Monika
Becker, Matthias
Ramos, Gema Morillas
Dulovic, Alex
Gruber, Jens
Juengling, Jennifer
Lürken, Karsten
Beigel, Andrea
Wrenger, Eike
Lonnemann, Gerhard
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2021-08-12
Submitted date
Files
Loading...
Open Access publication
Adobe PDF, 784.79 KB
Other Titles
Abstract
Background: Patients with chronic renal insufficiency on maintenance haemodialysis face an increased risk of COVID-19 induced mortality and impaired vaccine responses. To date, only a few studies have addressed SARS-CoV-2 vaccine elicited immunity in this immunocompromised population. Methods: We assessed immunogenicity of the mRNA vaccine BNT162b2 in at-risk dialysis patients and characterised systemic cellular and humoral immune responses in serum and saliva using interferon γ release assay and multiplex-based cytokine and immunoglobulin measurements. We further compared binding capacity and neutralization efficacy of vaccination-induced immunoglobulins against emerging SARS-CoV-2 variants Alpha, Beta, Epsilon and Cluster 5 by ACE2-RBD competition assay. Findings: Patients on maintenance haemodialysis exhibit detectable but variable cellular and humoral immune responses against SARS-CoV-2 and variants of concern after a two-dose regimen of BNT162b2. Although vaccination-induced immunoglobulins were detectable in saliva and plasma, both anti-SARS-CoV-2 IgG and neutralization efficacy was reduced compared to a vaccinated non-dialysed control population. Similarly, T-cell mediated interferon γ release after stimulation with SARS-CoV-2 spike peptides was significantly diminished. Interpretation: Quantifiable humoral and cellular immune responses after BNT162b2 vaccination in individuals on maintenance haemodialysis are encouraging, but urge for longitudinal follow-up to assess longevity of immunity. Diminished virus neutralization and interferon γ responses in the face of emerging variants of concern may favour this at-risk population for re-vaccination using modified vaccines at the earliest opportunity. Funding: Initiative and Networking Fund of the Helmholtz Association of German Research Centres, EU Horizon 2020 research and innovation program, State Ministry of Baden-Württemberg for Economic Affairs, Labour and Tourism.
Citation
EBioMedicine. 2021 Aug;70:103524. doi: 10.1016/j.ebiom.2021.103524. Epub 2021 Aug 12.
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
EISSN
2352-3964
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution-NonCommercial-NoDerivatives 4.0 International